Tyrosine kinase inhibitors (TKIs) are widely used in Oncology practice. Hypertension may develop during cancer treatment and TKIs are well known drugs that are associated with drug related hypertensive toxicity. TKI related hypertensive toxicity is not always the indicator of worse clinical outcomes and it may be the sign of treatment efficacy
Clinical outcomes for patients with a wide range of malignancies have improved substantially over th...
Background: Off-target effects in chronic myeloid leukemia (CML) patients treated with tyrosine kina...
Tyrosine kinase inhibitors (TKIs) have rapidly become an established factor in oncology, and have be...
Cancer treatment is an area of continuous improvement. Therapy is becoming more targeted and the use...
The treatment of thyroid cancer has promising prospects, mostly through the use of surgical or radio...
This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four tyrosine...
Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib...
Tyrosine kinase inhibitors (TKI) are a group of oral drugs, which are used to treat solid tumors. Th...
The increasing knowledge of the molecular mechanisms in the cell signaling pathways of malignant cel...
Tyrosine kinase inhibitors (TKI) belong to a new class of molecular multitargeted anticancer therapy...
International audienceTyrosine kinase inhibitors (TKIs) are currently used by most oncologists. Amon...
Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor rec...
Tyrosine kinase inhibitors (TKIs) are emerging as potentially effective options in the treatment of ...
Tyrosine kinases are important for the development of pathological angiogenesis, a critical factor f...
Contemporary anticancer drugs have significantly improved cancer survival at the expense of cardiova...
Clinical outcomes for patients with a wide range of malignancies have improved substantially over th...
Background: Off-target effects in chronic myeloid leukemia (CML) patients treated with tyrosine kina...
Tyrosine kinase inhibitors (TKIs) have rapidly become an established factor in oncology, and have be...
Cancer treatment is an area of continuous improvement. Therapy is becoming more targeted and the use...
The treatment of thyroid cancer has promising prospects, mostly through the use of surgical or radio...
This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four tyrosine...
Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib...
Tyrosine kinase inhibitors (TKI) are a group of oral drugs, which are used to treat solid tumors. Th...
The increasing knowledge of the molecular mechanisms in the cell signaling pathways of malignant cel...
Tyrosine kinase inhibitors (TKI) belong to a new class of molecular multitargeted anticancer therapy...
International audienceTyrosine kinase inhibitors (TKIs) are currently used by most oncologists. Amon...
Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor rec...
Tyrosine kinase inhibitors (TKIs) are emerging as potentially effective options in the treatment of ...
Tyrosine kinases are important for the development of pathological angiogenesis, a critical factor f...
Contemporary anticancer drugs have significantly improved cancer survival at the expense of cardiova...
Clinical outcomes for patients with a wide range of malignancies have improved substantially over th...
Background: Off-target effects in chronic myeloid leukemia (CML) patients treated with tyrosine kina...
Tyrosine kinase inhibitors (TKIs) have rapidly become an established factor in oncology, and have be...